Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1273.46 -33.23 (2.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1306.69 | 52 Week High | $88.16 | |||
| Open | $1304.15 | 52 Week Low | $67.88 | |||
| Day High | $1307.92 | P/E | 294.78 | |||
| Day Low | $1257.62 | EPS | $4.32 | |||
| Volume | 2,277,291 | |||||
